Kintara Therapeutics ( (KTRA) ) has issued an update.
Kintara Therapeutics, Inc. and TuHURA Biosciences, Inc. have announced their upcoming Special Meeting of Stockholders on their social media platforms, aiming to finalize their proposed merger. Investors and stockholders are urged to review the definitive proxy statement/prospectus and other relevant documents filed with the SEC for detailed information about the merger. These documents are crucial for making informed decisions and are freely available on the SEC website and through Kintara’s communication channels. The merger is subject to stockholder approval and other customary closing conditions, and the companies caution that forward-looking statements regarding the merger’s outcome are subject to various risks and uncertainties.
For detailed information about KTRA stock, go to TipRanks’ Stock Analysis page.
